抗菌药物耐药性领导组在革兰阴性菌感染研究中的优先事项与进展
抗菌药物耐药性领导组(ARLG)将耐药革兰阴性菌感染的治疗与预防列为优先领域,已开展系列观察性研究明确碳青霉烯类耐药和头孢曲松耐药肠杆菌目、碳青霉烯类耐药铜绿假单胞菌及鲍曼不动杆菌的全球临床与分子流行病学,并开展药代动力学研究和随机临床试验评估口服磷霉素降阶梯治疗及单剂静脉噬菌体疗法的安全性与有效性。
要点
- ARLG开展观察性研究明确耐药革兰阴性菌的全球临床与分子流行病学,以优化干预研究设计。
- ARLG开展药代动力学研究指导口服磷霉素、静脉米诺环素及头孢他啶-阿维巴坦联合氨曲南的给药方案。
- 随机临床试验评估口服磷霉素降阶梯治疗复杂性尿路感染及单剂静脉噬菌体疗法对囊性纤维化成人患者的安全性与有效性。
核心结论
- ARLG的研究重点已从增进对耐药革兰阴性菌感染的理解,演变为通过药代动力学与临床干预研究相结合来积极影响受影响患者的临床照护,并将继续维持这一重点。
研究设计与样本
- ARLG开展了一系列观察性研究、药代动力学研究和随机临床试验,旨在优化干预研究的设计与实施。
主要发现
- ARLG开展的观察性研究明确了碳青霉烯类耐药和头孢曲松耐药肠杆菌目、碳青霉烯类耐药铜绿假单胞菌及碳青霉烯类耐药鲍曼不动杆菌的全球临床与分子流行病学。
- 一项正在进行的ARLG研究旨在更好地理解耐药氟喹诺酮类肠道革兰阴性菌对中性粒细胞减少患者的影响,该问题可能削弱氟喹诺酮预防在这些脆弱患者中的有效性。
- ARLG开展了药代动力学研究,为口服磷霉素、静脉米诺环素以及静脉头孢他啶-阿维巴坦联合氨曲南等耐药革兰阴性菌治疗重要抗生素的最佳给药提供依据。
- 随机临床试验评估了口服磷霉素降阶梯治疗复杂性尿路感染以及单剂静脉噬菌体疗法对呼吸道慢性定植铜绿假单胞菌的囊性纤维化成人患者的安全性与有效性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies to define the clinical and molecular global epidemiology of carbapenem-resistant and ceftriaxone-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii, with the goal of optimizing the design and execution of interventional studies. One ongoing ARLG study aims to better understand the impact of fluoroquinolone-resistant gram-negative gut bacteria in neutropenic patients, which threatens to undermine the effectiveness of fluoroquinolone prophylaxis in these vulnerable patients. The ARLG has conducted pharmacokinetic studies to inform the optimal dosing of antibiotics that are important in the treatment of drug-resistant gram-negative bacteria, including oral fosfomycin, intravenous minocycline, and a combination of intravenous ceftazidime-avibactam and aztreonam. In addition, randomized clinical trials have assessed the safety and efficacy of step-down oral fosfomycin for complicated urinary tract infections and single-dose intravenous phage therapy for adult patients with cystic fibrosis who are chronically colonized with P. aeruginosa in their respiratory tract. Thus, the focus of investigation in the ARLG has evolved from improving understanding of drug-resistant gram-negative bacterial infections to positively affecting clinical care for affected patients through a combination of interventional pharmacokinetic and clinical studies, a focus that will be maintained moving forward.
引用
- Satlin MJ, van Duin D, Tamma PD, et al. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2023. PMID: 37843118. doi:10.1093/cid/ciad547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。